Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
RNXT
RNXT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RNXT News
RenovoRx Named 10th Most Innovative Medical Device Company by Fast Company
Apr 01 2026
Newsfilter
RenovoRx Reports Wider Net Loss Despite Revenue Growth in 2025
Mar 31 2026
NASDAQ.COM
RenovoRx Reports Strong 2025 Revenue Growth and Expansion Plans
Mar 31 2026
Yahoo Finance
RenovoRx Reports FY 2025 Financial Results with Private Placement
Mar 30 2026
seekingalpha
RENOVORX REPORTS FY OPERATING EXPENSES OF USD 13.306 MILLION
Mar 30 2026
moomoo
RENOVORX REPORTS FY NET LOSS OF USD 11.168 MILLION
Mar 30 2026
moomoo
Multiple Companies Set to Report Earnings
Mar 30 2026
NASDAQ.COM
RenovoRx TIGeR-PaC Trial Enrollment on Track for 2026 Completion
Mar 26 2026
Newsfilter
RenovoRx Secures $10 Million in Oversubscribed Private Placement
Mar 18 2026
seekingalpha
RenovoRx Expands RenovoCath Adoption Across U.S. Cancer Centers
Feb 28 2026
Yahoo Finance
RenovoRx Expands Market for Cancer Treatment Device
Feb 27 2026
Newsfilter
RenovoRx Clinical Data Abstract Accepted for Presentation at SIR 2026
Feb 26 2026
Newsfilter
Wall Street Analysts Adjust Ratings
Feb 17 2026
Benzinga
RenovoRx Forms Medical Advisory Board to Enhance Oncology Strategies
Feb 10 2026
Newsfilter
RenovoRx Announces New Clinical Data Presentation
Feb 04 2026
Newsfilter
Oncolytics Biotech's Breakthroughs in Cancer Treatment
Jan 30 2026
PRnewswire
Show More News
